ST Renfu Subsidiary Obtains Drug Registration Certificate for Carbamazepine Extended-Release Tablets (II)

Jiemian··Read original
2▲1 ▼0Impact / 5
Summary · why it matters

ST Renfu announced that its controlling subsidiary, Yichang Renfu, has received the Drug Registration Certificate for Carbamazepine Extended-Release Tablets (II) from the National Medical Products Administration, with specifications of 100 mg, 200 mg, and 400 mg, approved as a Category 3 chemical drug. The drug is primarily used to treat epilepsy and relieve trigeminal neuralgia. It was developed under dual filing standards for China and the United States and co-line production, and had already received an ANDA approval from the U.S. FDA in January 2025.

Impact on assets 1

Others▲ · 1 stocks
© 2026 MarketIVNews